Shattuck Labs (NASDAQ:STTK – Get Free Report) and Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.
Profitability
This table compares Shattuck Labs and Celldex Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Shattuck Labs | N/A | -43.57% | -40.90% |
| Celldex Therapeutics | N/A | -52.35% | -47.61% |
Volatility and Risk
Shattuck Labs has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.
Insider and Institutional Ownership
58.7% of Shattuck Labs shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Shattuck Labs and Celldex Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Shattuck Labs | 1 | 0 | 9 | 3 | 3.08 |
| Celldex Therapeutics | 1 | 1 | 11 | 0 | 2.77 |
Shattuck Labs currently has a consensus target price of $13.70, suggesting a potential upside of 134.59%. Celldex Therapeutics has a consensus target price of $63.08, suggesting a potential upside of 108.26%. Given Shattuck Labs’ stronger consensus rating and higher probable upside, analysts plainly believe Shattuck Labs is more favorable than Celldex Therapeutics.
Valuation and Earnings
This table compares Shattuck Labs and Celldex Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Shattuck Labs | $1.00 million | 586.10 | -$48.81 million | ($0.51) | -11.45 |
| Celldex Therapeutics | $1.54 million | 1,544.59 | -$258.76 million | ($4.35) | -6.96 |
Shattuck Labs has higher earnings, but lower revenue than Celldex Therapeutics. Shattuck Labs is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Shattuck Labs beats Celldex Therapeutics on 10 of the 13 factors compared between the two stocks.
About Shattuck Labs
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
About Celldex Therapeutics
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.
